Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBIT: 2018-2024

Historic EBIT for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$273.2 million.

  • Allogene Therapeutics' EBIT rose 37.44% to -$44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$227.4 million, marking a year-over-year increase of 23.64%. This contributed to the annual value of -$273.2 million for FY2024, which is 16.64% up from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' EBIT is -$273.2 million, which was up 16.64% from -$327.7 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' EBIT peaked at -$180.2 million during FY2021, and registered a low of -$335.5 million during FY2022.
  • Its 3-year average for EBIT is -$312.2 million, with a median of -$327.7 million in 2023.
  • Per our database at Business Quant, Allogene Therapeutics' EBIT surged by 30.22% in 2021 and then tumbled by 86.21% in 2022.
  • Yearly analysis of 5 years shows Allogene Therapeutics' EBIT stood at -$258.2 million in 2020, then soared by 30.22% to -$180.2 million in 2021, then crashed by 86.21% to -$335.5 million in 2022, then increased by 2.32% to -$327.7 million in 2023, then grew by 16.64% to -$273.2 million in 2024.